Key Points
CBD appears to be useful in treating alcohol use disorder, otherwise known as alcoholism.
It reduced withdrawal symptoms, and curbed relapse, in rodents during a clinical trial.
10 stocks we like better than Curaleaf ›
Marijuana stock Curaleaf (OTC: CURLF) got quite a buzz Thursday from news about one of the substances for which it’s best known. Interestingly enough, this was not the THC that gets people high from consuming marijuana, but cannabidiol (CBD), the nonpsychoactive compound that’s also packed into the plant.
On reports of a previously undetected potential health benefit of CBD, investors piled into Curaleaf stock and pushed its value nearly 10% higher on the day.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
What the drunk rodents were telling us
Industry newsletter reported that the results of a clinical study indicate that CBD appeared to improve withdrawal and relapse conditions in those suffering from alcohol use disorder (more commonly known simply as alcoholism).
Citing a report on the study published in the scientific journal Nature, Marijuana Moment said that researchers at the University of California, San Diego conducted the clinical trial on rodents.
Two cohorts among 166 of the animals were given shots of synthetic CBD, and another was used as a control group. The rodents that ingested the CBD demonstrated milder alcohol withdrawal symptoms and had a lower risk of relapse.
Seeing a way back to CBD?
That news is encouraging, not only because of the potential new use for CBD to help treat a stubborn condition. The study was partially funded by the federal government’s National Institute on Alcohol Abuse and Alcoholism, which might at least slightly tilt officialdom’s sentiment on marijuana-derived substances.
CBD is by no means a major part of Curaleaf’s business. The compound had its moment of popularity some years ago, but has since devolved into basically a low-profile niche product. Other successful studies like this, however, could lead to something of a revival.
Should you invest $1,000 in Curaleaf right now?
Before you buy stock in Curaleaf, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Curaleaf wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $654,624!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,075,117!*
Now, it’s worth noting Stock Advisor’s total average return is 1,049% — a market-crushing outperformance compared to 183% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 18, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
